Reference SummaryWattenberg LW, Carcinogenesis 2000 Feb;21(2):179-82

Title

Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol.

Authors

Wattenberg LW; Wiedmann TS; Estensen RD; Zimmerman CL; Galbraith AR; Steele VE; Kelloff GJ

Journal

Carcinogenesis

Volume

21

Issue

2

Year

2000

Pages

179-82

Abstract

This investigation is part of an effort to develop chemoprevention for carcinogenesis of the lung. It focuses on the efficacy of low doses of synthetic glucocorticoids administered either as single agents or in combination with a second compound, myo-inositol. Glucocorticoids are potent inhibitors of carcinogenesis. The use of low doses is important to avoid potential side-effects. The synthetic glucocorticoid budesonide, administered by aerosol for 20 s three times a week, was studied to determine its effects on benzo[a]pyrene-induced pulmonary adenoma formation in female A/J mice. Two dose levels were employed, 10 and 25 microg/kg body wt. The lower dose produced a 34% reduction in lung tumor formation and the higher dose level a 60% reduction in lung tumors. In additional groups of mice, the effects of 0.3% myo-inositol added to the diet was found to reduce pulmonary tumor formation by 53%. The two agents given in combination resulted in a greater inhibition of lung tumor formation than either by itself. Budesonide at 10 microg/kg body wt plus 0.3% myo-inositol reduced the number of tumors by 60% and budesonide at 25 microg/kg body wt plus 0.3% myo-inositol reduced lung tumor formation by 79%. To determine whether a glucocorticoid other than budesonide would have inhibitory effects in this experimental model, beclomethasone dipropionate administered by aerosol for 20 s three times a week was studied as a single agent and showed almost identical inhibitory properties to budesonide. The doses of the glucocorticoids calculated on a daily basis are within the range of those used widely for control of chronic allergic respiratory diseases in the human. The capacity of low doses of inhaled glucocorticoids to prevent pulmonary neoplasia and the enhancement of this preventive effect by myo-inositol, an essentially non-toxic compound, are findings that should encourage further work to evaluate the applicability of these agents to the prevention of neoplasia of the lung in the human.

Links

J:60825 – MGI References
10657955 – National Library of Medicine/PubMed

Models

Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
A/J Lung adenoma
  • benzo[a]pyrene (BP) (BaP) (B[a]P)
Lung

very high

A/J Lung adenoma
  • budesonide
  • benzo[a]pyrene (BP) (BaP) (B[a]P)
Lung

very high

A/J Lung adenoma
  • benzo[a]pyrene (BP) (BaP) (B[a]P)
  • myo-inositol
Lung

very high

A/J Lung adenoma
  • budesonide
  • benzo[a]pyrene (BP) (BaP) (B[a]P)
  • myo-inositol
Lung

very high

A/J Lung adenoma
  • benzo[a]pyrene (BP) (BaP) (B[a]P)
  • beclomethasone dipropionate
Lung

very high